JP7671245B2 - ピリダジノン化合物およびその使用 - Google Patents

ピリダジノン化合物およびその使用 Download PDF

Info

Publication number
JP7671245B2
JP7671245B2 JP2021524226A JP2021524226A JP7671245B2 JP 7671245 B2 JP7671245 B2 JP 7671245B2 JP 2021524226 A JP2021524226 A JP 2021524226A JP 2021524226 A JP2021524226 A JP 2021524226A JP 7671245 B2 JP7671245 B2 JP 7671245B2
Authority
JP
Japan
Prior art keywords
alkyl
optionally substituted
halogen
independently selected
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021524226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506686A (ja
JP2022506686A5 (https=
Inventor
ケビン ハント，
ケビン コック，
アラン ラッセル，
スティーブン シュラクター，
ポール ウィンシップ，
グレース ウゾホ，
クリス スティール，
Original Assignee
エッジワイズ セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エッジワイズ セラピューティクス， インコーポレイテッド filed Critical エッジワイズ セラピューティクス， インコーポレイテッド
Publication of JP2022506686A publication Critical patent/JP2022506686A/ja
Publication of JP2022506686A5 publication Critical patent/JP2022506686A5/ja
Priority to JP2024226318A priority Critical patent/JP2025041790A/ja
Application granted granted Critical
Publication of JP7671245B2 publication Critical patent/JP7671245B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021524226A 2018-11-06 2019-11-06 ピリダジノン化合物およびその使用 Active JP7671245B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024226318A JP2025041790A (ja) 2018-11-06 2024-12-23 ピリダジノン化合物およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862756552P 2018-11-06 2018-11-06
US62/756,552 2018-11-06
PCT/US2019/060148 WO2020097258A1 (en) 2018-11-06 2019-11-06 Pyridazinone compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024226318A Division JP2025041790A (ja) 2018-11-06 2024-12-23 ピリダジノン化合物およびその使用

Publications (3)

Publication Number Publication Date
JP2022506686A JP2022506686A (ja) 2022-01-17
JP2022506686A5 JP2022506686A5 (https=) 2022-11-14
JP7671245B2 true JP7671245B2 (ja) 2025-05-01

Family

ID=69326619

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021524226A Active JP7671245B2 (ja) 2018-11-06 2019-11-06 ピリダジノン化合物およびその使用
JP2024226318A Pending JP2025041790A (ja) 2018-11-06 2024-12-23 ピリダジノン化合物およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024226318A Pending JP2025041790A (ja) 2018-11-06 2024-12-23 ピリダジノン化合物およびその使用

Country Status (7)

Country Link
US (2) US11390606B2 (https=)
EP (1) EP3877367B1 (https=)
JP (2) JP7671245B2 (https=)
CN (1) CN113272280B (https=)
AU (1) AU2019374812B2 (https=)
CA (1) CA3118904A1 (https=)
WO (1) WO2020097258A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021514010A (ja) * 2018-02-20 2021-06-03 エッジワイズ セラピューティクス， インコーポレイテッド 運動障害を処置するための方法および組成物
WO2020097258A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
ES2958954T3 (es) * 2018-11-06 2024-02-16 Edgewise Therapeutics Inc Compuestos de piridazinona y usos de los mismos
EP3877052B1 (en) 2018-11-06 2023-08-16 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
IL285067B2 (en) 2019-01-22 2025-02-01 Aeovian Pharmaceuticals Inc MTORC Modulators and Their Uses
JP7758687B2 (ja) * 2020-05-13 2025-10-22 エッジワイズ セラピューティクス， インコーポレイテッド 神経筋疾患の処置のためのピリダジノン化合物
WO2021231546A1 (en) * 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
WO2021231615A1 (en) * 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
WO2021231630A1 (en) * 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
EP4149620B1 (en) * 2020-05-13 2024-10-23 Edgewise Therapeutics, Inc. Pyridazinone compounds for the treatment of neuromuscular diseases
JP2025530218A (ja) 2022-09-09 2025-09-11 エッジワイズ セラピューティクス， インコーポレイテッド 神経筋の状態の処置のためのピリダジノン組成物
JP2026501712A (ja) * 2023-01-04 2026-01-16 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド ピリダジノンヘテロ環化合物Ｍｙｏｓｉｎ ＩＩ阻害剤及びその用途
WO2025167826A1 (zh) * 2024-02-06 2025-08-14 西藏海思科制药有限公司 三环化合物作为Myosin II抑制剂及其用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095666A1 (ja) 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2009518323A (ja) 2005-12-05 2009-05-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 腫瘍治療用のピリジアジノン誘導体
JP2010528994A (ja) 2007-06-01 2010-08-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アリールエーテルピリダジノン誘導体
JP2010528995A (ja) 2007-06-01 2010-08-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリダジノン誘導体
JP2016508505A (ja) 2013-02-07 2016-03-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリダジノン−アミド誘導体
WO2017028798A1 (zh) 2015-08-19 2017-02-23 中国科学院上海药物研究所 哒嗪酮类化合物、其制备方法、药物组合物及用途

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6140270A (ja) 1984-08-01 1986-02-26 Morishita Seiyaku Kk ピリダジノン誘導体
DD286354A5 (de) 1989-08-08 1991-01-24 Karl-Marx-Universitaet Leipzig,De Verfahren zur herstellung substituierter 2-carbamoyl-methyl-4-phenyl-1,2,5,6-tetrahydro- und 1,2-dihydro-1-oxo-pyridazine
DE69131268T2 (de) 1990-09-21 1999-12-30 Rohm And Haas Co., Philadelphia Dihydropyridazinone und Pyridazinone als Fungizide
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
DE19629817A1 (de) 1996-07-24 1998-01-29 Hoechst Ag Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
NZ522882A (en) 2000-06-05 2004-07-30 Altana Pharma Bv Pyridazinone compounds effective as beta-2-adrenoreceptor agonists as well as PDE4-inhibitors
WO2004022540A2 (en) 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
BRPI0407519A (pt) * 2003-03-07 2006-02-14 Kowa Co derivados de benzofurano
WO2007044796A2 (en) 2005-10-11 2007-04-19 Nps Pharmaceuticals, Inc. Pyridazinone compounds as calcilytics
HRP20130044T1 (hr) 2006-07-25 2013-02-28 Cephalon, Inc. Derivati piridizinona
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
DE102007038957A1 (de) 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
WO2009142732A2 (en) 2008-05-20 2009-11-26 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
WO2010048149A2 (en) 2008-10-20 2010-04-29 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
WO2012021707A2 (en) * 2010-08-11 2012-02-16 The Regents Of The University Of California Premature-termination-codons readthrough compounds
US8975260B2 (en) 2010-09-01 2015-03-10 Genetech, Inc Pyridazinones, method of making, and method of use thereof
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
WO2013057101A1 (de) 2011-10-17 2013-04-25 Bayer Intellectual Property Gmbh Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer
CN103570730A (zh) 2012-08-01 2014-02-12 中国科学院上海药物研究所 具有桥环结构的稠环哒嗪酮类化合物及其制备方法和用途
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
US9566310B2 (en) 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
US9216180B2 (en) 2012-10-02 2015-12-22 New York University Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay
JP2016507496A (ja) * 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
EP2968323A4 (en) 2013-03-13 2016-12-14 Flatley Discovery Lab PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
WO2014189634A1 (en) 2013-04-19 2014-11-27 University Of Iowa Research Foundation Angiotensins in muscular dystrophy
CA2987980A1 (en) 2015-06-05 2016-12-08 Ptc Therapeutics, Inc. Use of an aminoglycoside for nonsense mutation suppression and the treatment of disease
EP3307891B8 (en) 2015-06-10 2019-11-13 Association Institut de Myologie Combined therapy for duchenne muscular dystrophy
WO2017046117A1 (en) * 2015-09-15 2017-03-23 Abbvie Inc. Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use
CA3041675A1 (en) * 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis
WO2018081378A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
WO2018081381A1 (en) 2016-10-26 2018-05-03 Proteostasis Therapeutics, Inc Pyridazine derivatives, compositions and methods for modulating cftr
CN110573161A (zh) 2017-03-28 2019-12-13 勃林格殷格翰国际有限公司 用于治疗肌营养不良的方法的尼达尼布
TWI829634B (zh) 2017-04-06 2024-01-21 美商富曼西公司 殺真菌之噁二唑
US20180303821A1 (en) 2017-04-24 2018-10-25 BraneQuest, Inc. Membrane active molecules
BE1025518B1 (fr) 2017-08-30 2019-04-03 E2 Drives Sa Groupe motopropulseur
US11065243B2 (en) 2017-10-27 2021-07-20 Sonic Master Limited Inhibitors of DUX4 induction for regulation of muscle function
JP7623680B2 (ja) 2018-05-17 2025-01-29 ボルト スレッズ インコーポレイテッド 組換えタンパク質の分泌を改善するためのｓｅｃ改変株
EP4685140A1 (en) 2018-06-04 2026-01-28 Ohio State Innovation Foundation Eaat2 activators and methods of using thereof
EP3828174A4 (en) 2018-07-19 2022-08-17 Sumitomo Pharma Co., Ltd. PYRIDAZINONE DERIVATIVE
CN108947912B (zh) 2018-07-31 2021-10-01 中国人民解放军总医院 一种靶向Neddylation通路的抗肿瘤化合物
ES2958954T3 (es) 2018-11-06 2024-02-16 Edgewise Therapeutics Inc Compuestos de piridazinona y usos de los mismos
WO2020097258A1 (en) 2018-11-06 2020-05-14 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
EP3877052B1 (en) 2018-11-06 2023-08-16 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
WO2021231615A1 (en) 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
WO2021231546A1 (en) 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
WO2021231630A1 (en) 2020-05-13 2021-11-18 Edgewise Therapeutics, Inc. Substituted pyridazinone for use in the treatment of neuromuscular diseases
EP4149620B1 (en) 2020-05-13 2024-10-23 Edgewise Therapeutics, Inc. Pyridazinone compounds for the treatment of neuromuscular diseases
JP7758687B2 (ja) 2020-05-13 2025-10-22 エッジワイズ セラピューティクス， インコーポレイテッド 神経筋疾患の処置のためのピリダジノン化合物
JP7694135B2 (ja) 2021-05-11 2025-06-18 株式会社大林組 接続構造及び接続方法
EP4433473A1 (en) 2021-11-17 2024-09-25 Edgewise Therapeutics, Inc. Pyridazinone compounds and uses thereof
EP4522599A1 (en) 2022-05-11 2025-03-19 Edgewise Therapeutics, Inc. Methods of manufacturing pyridazinone compounds
JP2025530218A (ja) 2022-09-09 2025-09-11 エッジワイズ セラピューティクス， インコーポレイテッド 神経筋の状態の処置のためのピリダジノン組成物
JP2025040270A (ja) * 2023-09-11 2025-03-24 共同印刷株式会社 赤外線遮断性生地

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095666A1 (ja) 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2009518323A (ja) 2005-12-05 2009-05-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 腫瘍治療用のピリジアジノン誘導体
JP2010528994A (ja) 2007-06-01 2010-08-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アリールエーテルピリダジノン誘導体
JP2010528995A (ja) 2007-06-01 2010-08-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリダジノン誘導体
JP2016508505A (ja) 2013-02-07 2016-03-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ピリダジノン−アミド誘導体
WO2017028798A1 (zh) 2015-08-19 2017-02-23 中国科学院上海药物研究所 哒嗪酮类化合物、其制备方法、药物组合物及用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
2-(4-CHLOROBENZYL)-6-(4-ETHOXYPHENYL)PYRIDAZIN-3(2H)-ONE，PUBCHEM CID 7662323，2006年07月29日，PAGE(S):1-8，https://pubchem.ncbi.nlm.nih.gov/compound/7662323
E. CEPEDA; ET AL，FUNCTIONAL PROPERTIES OF FABA BEAN (VICIA FABA) PROTEIN FLOUR DRIED BY SPRAY DRYING AND FREEZE DRYIN，JOURNAL OF FOOD ENGINEERING，英国，1998年05月01日，VOL:36, NR:3，PAGE(S):303-310，https://doi.org/10.1016/S0260-8774(98)00061-2
European Journal of Medicinal Chemistry，2016年，108，322-333
J. Comb. Chem.，2005年，7，414-420
J. Med. Chem. ，2011年，54，4781-4792
REGISTRY(STN)[online]，検索日2023年11月13日:2011.12.07 RN:1350041-75-6, 2010. 7.16 RN:1232768-39-6, 2007. 2.26 RN:923076-66-8, 2007. 2.23 RN:922973-89-5

Also Published As

Publication number Publication date
US20210130327A1 (en) 2021-05-06
JP2022506686A (ja) 2022-01-17
EP3877367A1 (en) 2021-09-15
JP2025041790A (ja) 2025-03-26
CA3118904A1 (en) 2020-05-14
CN113272280B (zh) 2026-01-09
AU2019374812A1 (en) 2021-06-10
CN113272280A (zh) 2021-08-17
US11390606B2 (en) 2022-07-19
AU2019374812B2 (en) 2025-03-06
EP3877367B1 (en) 2024-05-22
WO2020097258A1 (en) 2020-05-14
US20230048816A1 (en) 2023-02-16
US12240833B2 (en) 2025-03-04

Similar Documents

Publication Publication Date Title
JP7671245B2 (ja) ピリダジノン化合物およびその使用
JP7357135B2 (ja) ピリダジノン化合物およびその使用
JP7429750B2 (ja) ピリダジノン化合物およびその使用
JP7606537B2 (ja) 神経筋疾患の処置のためのピリダジノン化合物
WO2021231630A1 (en) Substituted pyridazinone for use in the treatment of neuromuscular diseases
JP2024540485A (ja) ピリダジノン化合物およびその使用
EA050889B1 (ru) Соединения пиридазинонов и их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221104

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231116

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240516

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241223

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250417

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250418

R150 Certificate of patent or registration of utility model

Ref document number: 7671245

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150